Radiation will yield

Five-day-old zebrafish embryos under a microscope: the normal embryo (top) and the transgenic embryo (bottom) carrying the gene with the disease-causing mutation. It can be seen that in the transgenic embryo the main lymphatic vessel is abnormally enlarged

From the clinic to the aquarium: New zebrafish-based drugs for a rare lymphatic disease

A unique collaboration between the Weizmann Institute of Science and Sheba Medical Center led to the discovery of two potential drugs for a life-threatening disease of the lymphatic system.
Cross section of the zebrafish heart 30 days after injury. The injured site (marked by an arrow) without a scar in a fish with normal lymphatic vessels (left) but not in a mutant fish that does not have these vessels (right)

heart of a fish

Transient aging: Zebrafish (top row), newborn mouse (middle row) and adult mouse (bottom row) hearts are seen (left column) with almost no senescent fibroblasts (indicated in turquoise). After injury to the heart muscle (accompanying agrin injections in an adult mouse), many fibroblasts went into a state of senescence (middle column), which passed about three weeks later (right column)

Aging cells, young heart

The endothelial cells, which make up the blood vessels of the zebrafish embryo (in red). The cell nuclei are marked in yellow. The stem cell pool is marked with an arrow

Wandering with gut feeling

From the right: Dr. Karina Yaniv, Guy Melkinson, Inbal Avraham-Davidi, Moshe Greenspan, Liron Gibbs Bar, Oded Meisels and Yona Eli. Dialogue. Photo: Weizman Institute

Dialogue in the dark

Dr. Karina Yaniv. Molecular signals

between the fat and the blood